-
Anadys Announces Issuance of U.S. Patent Covering Setrobuvir (ANA598)
Wednesday, June 1, 2011 - 4:10pm | 131Anadys Pharmaceuticals (Nasdaq: ANDS) today announced issuance of the U.S. patent covering setrobuvir (ANA598), the Company's Direct-Acting Antiviral in Phase IIb development for chronic hepatitis C virus infection. U.S. Patent No. 7,939,524, granted to Anadys by the United States Patent and...
-
Aastrom Demonstrates Statistically Significant Improvement in Time to First Occurrence of Treatment Failure at 12 Months in RESTORE-CLI Clinical Trial
Wednesday, June 1, 2011 - 4:06pm | 102Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic, cardiovascular diseases, today announced that the final analysis of data from all 86 randomized patients in the RESTORE-CLI trial showed that...
-
Biotech/Pharma Investor Trading Alert; BioSante Pharmaceuticals, Inc. Moves to New Trading Levels Following Breakout of 52 Week High
Wednesday, June 1, 2011 - 2:15pm | 955Point Roberts, WA, LINCOLNSHIRE, Ill - June 1, 2011 - Investorideas.com, a leader in sector stock research for independent investors, issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX). The stock has reached as high as $3.20 following yesterday'...
-
Orexigen Therapeutics Trading Over 14% Higher Today
Wednesday, June 1, 2011 - 12:44pm | 51Orexigen Therapeutics Inc (NASDAQ: OREX) shares advanced 19.43% to $3.38 at 9:49 am. OREX is scheduled to announce a regulatory update on Contrave NDA on June 3, 2011 before the opening bell. Read more here.
-
Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer
Wednesday, June 1, 2011 - 12:13pm | 225Hapoalim Securities is terminating coverage of Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), Pfizer (NYSE: PFE), Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS), Amarin (NASDAQ: AMRN), Amylin (NASDAQ: AMLN), Arena Pharmaceuticals (NASDAQ: ARNA), Auxilium (NASDAQ: AUXL),...
-
Hapoalim Cutting Ocverage On Multitude Of Names
Wednesday, June 1, 2011 - 11:48am | 237Hapoalim Securities announced it would be terminating coverage of a slew of pharmaceutical names due to an analyst departure. The names affected are Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY) Merck (NYSE: MRK) Pfizer (NYSE: PFE) Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS) Amarin (NASDAQ:...
-
Options Brief: Celsion Corporation
Wednesday, June 1, 2011 - 10:13am | 75Shares of Celsion Corporation (NASDAQ: CLSN) are lower on the session by 5.57%, trading at $2.88. Overall call volume is now running at 7.12x the daily average, with 0% of all calls traded being purchases on the offer. 2,642 contracts have traded on the session so far. Celsion Corporation is an...
-
Morning Market Movers
Wednesday, June 1, 2011 - 9:57am | 123Orexigen Therapeutics Inc (NASDAQ: OREX) shares advanced 19.43% to $3.38 at 9:49 am. OREX is scheduled to announce a regulatory update on Contrave NDA on June 3, 2011 before the opening bell. Telvent GIT SA (NASDAQ: TLVT) climbed 15.36% to $39.74. TLVT agreed to be bought for $2 billion by...
-
Jefferies & Company Reports on United Therapeutics
Wednesday, June 1, 2011 - 8:29am | 145Jefferies & Company commented on United Therapeutics (NASDAQ: UTHR) in a report released today. In the report, Jefferies was mixed in its assessment of the company. Jefferies writes, "We epxect Ph3 monotherapy study for oral treprostinil (FREEDOM-M) to succeed (data in June); we focus on...
-
Jefferies Provides Color on Myriad Genetics, Buy
Wednesday, June 1, 2011 - 7:27am | 164Jefferies provided color on Myriad Genetics (NASDAQ: MYGN). In a research report published today, Jefferies commented on the Molecular Pathology Coding Workgroup meeting. In a research report published today, Jefferies states, "In conjunction with AMA's new coding initiative for molecular...
-
Jefferies Reiterates Buy on Biogen Idec
Wednesday, June 1, 2011 - 7:19am | 139Jefferies reiterated its Buy rating on Biogen Idec (NASDAQ: BIIB) after a meeting with a leading multiple sclerosis expert. In a research report published today, Jefferies stressed that the expert believes some of Biogen's products will perform very well. In the report, Jefferies states, "We had...
-
PDL BioPharma Provides Second Quarter 2011 Revenue Guidance of $128 Million vs $126 Million Estimate
Wednesday, June 1, 2011 - 7:07am | 84PDL BioPharma (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2011, of approximately $128 million, as compared with actual results of $120 million for the second quarter of 2010, an expected seven percent year-over-year increase. The forecasted growth is...
-
Repligen Concludes Pre-NDA Meeting with FDA for RG1068
Wednesday, June 1, 2011 - 7:02am | 166Repligen Corporation (NASDAQ: RGEN) today announced that the Company has concluded a pre-New Drug Application meeting with the U.S. Food and Drug Administration related to its lead product candidate, RG1068 for improvement of magnetic resonance imaging of the pancreas. The purpose of the meeting...
-
FDA Grants Priority Review for Alexion's sBLA for Soliris as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome
Wednesday, June 1, 2011 - 6:59am | 73Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome. A...
-
Top 4 Setups for Wednesday
Tuesday, May 31, 2011 - 5:43pm | 1793( click to enlarge ) Shares of DryShips Inc. (NASDAQ:DRYS) rose 8% to $4.05 cents per share. The technical chart above shows the stock could still go higher as %K line is rising on top of %D line indicating buy signal. In addition, ROC is still at oversold level and could attract bargain...